Search
Tacrolimus
go.drugbank.com/drugs/DB00864ApprovedInvestigationalTacrolimus (also FK-506 or Fujimycin) is an immunosuppressive drug whose main use is after organ transplant to reduce the activity of the patient's immune system and so the risk of organ rejection. … It was discovered in 1984 from the fermentation broth of a Japanese soil sample that contained the bacteria Streptomyces tsukubaensis. Tacrolimus is chemically known as a macrolide.
Categories: Agents for Dermatitis, Excluding Corticosteroids, P-glycoprotein substrates with a Narrow Therapeutic IndexProducts: Envarsus Pa, PROGRAF CONCENTRATE FOR INFUSION 5 mg/mlGedatolisib
go.drugbank.com/drugs/DB11896ApprovedInvestigational[L63927] Its approval also addresses a population defined by the absence of a biomarker, as patients with PIK3CA wild-type disease were not eligible for the PI3Kα-selective options. … [L63796,L63927] The PI3K/AKT/mTOR pathway is a long-standing target in the breast cancer setting, with previously approved agents acting on a single node of it (i.e. PI3Kα, AKT, or mTORC1).
Carglumic acid
go.drugbank.com/drugs/DB06775ApprovedInvestigationalCarglumic acid is a drug used for the treatment of hyperammonemia in patients with a deficiency in N-acetyl glutamate synthase.
Synonyms: N-Carbamyl-L-glutamate, Carbamino-L-glutamic acidSepiapterin
go.drugbank.com/drugs/DB16326ApprovedInvestigational[L53548,L53593] Sepiapterin was granted marketing authorization by the European Commission in June 2025 and by the US FDA in July 2025 for the treatment of adults and children with phenylketonuria. … Sepiapterin is a small molecule activator of phenylalanine hydroxylase (PAH) used to reduce phenyalanine levels in patients with phenylketonuria.
Synonyms: L-sepiapterinVandetanib
go.drugbank.com/drugs/DB05294ApprovedInvestigationalVandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. … On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients.
Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexAmmonia
go.drugbank.com/drugs/DB11118ApprovedInvestigationalIt is a colorless gas with a pungent smell, and become NH4, or ammonium ion, when in water. … The radiolabelled form of ammonia, ammonia N 13, is intravenously administered as a radioactive diagnostic agent for Positron Emission Tomography (PET) imaging of the myocardium to evaluate myocardial
Mixtures: JACK Smelling Salts for Athletes and Eucalyptus OilMosunetuzumab
go.drugbank.com/drugs/DB15434ApprovedInvestigationalHowever, patients with certain types of B-cell lymphoma, such as follicular lymphoma (FL), chronic lymphocytic leukemia (CLL) or aggressive B-cell lymphoma, have a high probability of relapse or recurrence … Mosunetuzumab is a humanized anti-CD20/CD3 bispecific antibody.
Products: Lunsumio 1mg/ml Concentrate for Solution for InfusionRotigotine
go.drugbank.com/drugs/DB05271ApprovedInvestigationalRotigotine has been authorized as a treatment for RLS since August 2008. … Rotigotine (Neupro) is a non-ergoline dopamine agonist indicated for the treatment of Parkinson's disease (PD) and restless legs syndrome (RLS) in Europe and the United States.
Somatostatin
go.drugbank.com/drugs/DB09099ApprovedInvestigationalWithdrawnSomatostatin, also known as growth hormone-inhibiting hormone, is a naturally-occurring peptide hormone of 14 or 28 amino acid residues [T28] that regulates the endocrine system. … [DB00104] is a long-acting analogue of somatostatin that inhibits the release of a number of hormones, and is clinically used to relieve symptoms of uncommon gastroenteropancreatic endocrine tumours, as
Products: STILAMIN 3000 FOR INJECTION 3 mg/ampouleCR665
go.drugbank.com/drugs/DB05155ExperimentalIn preclinical studies, CR665 was highly selective for the peripheral kappa opioid receptor. Preclinical animal studies suggest that CR665 is a potent analgesic compound. … CR665 is the lead clinical development candidate from a series of highly selective peripheral kappa opioid receptor agonists.